These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16309580)

  • 1. Effect of omapatrilat on the aging process of the normal rat.
    Basso N; Paglia N; Cini R; Inserra F; Terragno NA
    Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):557-64. PubMed ID: 16309580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
    Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
    Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
    Ferrario CM; Averill DB; Brosnihan KB; Chappell MC; Iskandar SS; Dean RH; Diz DI
    Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
    Ferrario CM; Smith RD; Brosnihan B; Chappell MC; Campese VM; Vesterqvist O; Liao WC; Ruddy MC; Grim CE
    Am J Hypertens; 2002 Jun; 15(6):557-64. PubMed ID: 12074359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
    Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.
    Varagic J; Susic D; Slama M; Frohlich ED
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):167-74. PubMed ID: 12808490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of the inhibition of the renin-angiotensin system on aging.
    Basso N; Paglia N; Stella I; de Cavanagh EM; Ferder L; del Rosario Lores Arnaiz M; Inserra F
    Regul Pept; 2005 Jun; 128(3):247-52. PubMed ID: 15837534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
    Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
    Uhlenius N; Vuolteenaho O; Tikkanen I
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.